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Abstract
Background: Trials of aspiration thrombectomy (AT) prior to primary percutaneous intervention (PCI) in patients
with ST-segment elevation MI (STEMI) have shown apparently inconsistent results and therefore generated
uncertainty and controversy. To summarize the effects of AT prior to PCI versus conventional PCI in STEMI patients.
Methods: Searches of MEDLINE, EMBASE and CENTRAL to June 2015 and review of reference lists of previous
reviews. We included randomized controlled trials (RCTs) comparing AT prior to PCI with conventional PCI alone.
Pairs of reviewers independently screened eligible articles; extracted data; and assessed risk of bias. We used the
GRADE approach to rate overall certainty of the evidence.
Results: Among 73 potential articles identified, 20 trials including 21,660 patients were eligible; data were complete
for 20,866 patients. Moderate-certainty evidence suggested a non statistically significant decrease in overall
mortality (risk ratio (RR) 0.89, 95 % confidence interval, 0.78 to 1.01, risk difference (RD) 4/1,000 over 6 months), no
impact on recurrent MI (RR 0.94, 95 % CI, 0.79 to 1.12) or major bleeding (RR 1.02, 95 % CI, 0.78 to 1.35), and an
increase in stroke (RR 1.56, 95 % CI, 1.09 to 2.24, RD 3/1,000 over 6 months).
Conclusions: Moderate certainty evidence suggests aspiration thrombectomy is associated with a possible small
decrease in mortality (4 less deaths/1000 over 6 months) and a small increase in stroke (3 more strokes/1000 over
6 months). Because absolute effects are very small and closely balanced, thrombectomy prior to primary PCI should
not be used as a routine strategy.
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Background
In patients with ST-segment elevation myocardial infarc-
tion (STEMI), primary percutaneous coronary interven-
tion (PCI) rapidly restores myocardial flow resulting in
decreased infarct size and decreased mortality compared
to thrombolysis or conservative medical management
[1]. Some patients may, however, experience distal
embolization of thrombus and plaque debris with failure
to adequately restore distal microcirculatory flow. This
“no reflow” phenomenon is associated with an increase
in infarct size and lower survival [2].
Randomized clinical trials (RCTs) comparing aspiration
or mechanical thrombectomy prior to primary PCI to PCI
alone have shown improvement in markers of myocardial
reperfusion (e.g. “myocardial blush”, ST-segment resolution
post procedure) [3]. A recent meta-analysis of 20 RCTs ad-
dressing patient-important outcomes and including over
11,000 patients reported that aspiration thrombectomy
prior to primary PCI was associated with a reduction in
major coronary adverse events and 1-year mortality [4]. A
more recent meta-analysis including 26 RCTs, reported a
different conclusion: aspiration thrombectomy did not
* Correspondence: fspence@mcmaster.ca
3Division of Cardiology, Department of Medicine, McMaster University, St.
Joseph’s Healthcare - 50 Charlton Avenue East, Hamilton, Ontario, Canada
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
El Dib et al. BMC Cardiovascular Disorders  (2016) 16:121 
DOI 10.1186/s12872-016-0285-4
improve clinical outcomes [5]. Neither of these meta-
analyses included the recently published Trial of Routine
Aspiration Thrombectomy with PCI versus PCI Alone in
Patients with STEMI (TOTAL), which randomized over
10,000 patients [6].
We therefore undertook a systematic review of all
RCTs comparing aspiration thrombectomy prior to PCI
versus PCI alone in patients with STEMI, focusing on
patient-important outcomes. As composite endpoints
varied between trials and can produce misleading results
[7, 8], we focused on individual endpoints of overall
mortality, recurrent MI, stroke, and major bleeding.
Methods
This review adheres to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) State-
ment [9]; the Quality of Reporting of Meta-analyses
QUOROM [10]; and the Cochrane Handbook for Sys-
tematic Reviews of Interventions [11].
Eligibility criteria
We included RCTs that compared aspiration thrombec-
tomy prior to PCI with conventional PCI in patients
with STEMI, included any one of the following patient-
important outcomes: overall mortality, cardiovascular
(CV) mortality, myocardial infarction (MI), stroke (in-
cluding ischemic and hemorrhagic stroke) and, non-fatal
extracranial major bleeding, and followed patients for at
least 30 days. We excluded studies reported only as con-
ference abstracts.
Data source and searches
A previous review with similar inclusion criteria identi-
fied studies up to December 2013 [5]. Using Medical
Subject Headings (MeSH) based on the terms “thromb-
ectomy,” “thrombus aspiration,” “thromboaspiration,”
“infarction,” and “myocardial infarction” (Appendix
Table 1) we replicated the search strategy of that review
[5] for Medline, EMBASE, and Cochrane Controlled Tri-
als Register (CENTRAL) from January 1, 2014 to June
26, 2015. We also reviewed reference lists of relevant re-
view articles [4, 5, 12] and primary studies.
Selection of studies
Teams of two reviewers independently screened all titles
and abstracts identified by the literature search, obtained
full-text articles of all potentially eligible studies, and
evaluated these studies for eligibility criteria.
Data extraction and risk of bias assessment
Three pairs of reviewers independently extracted the fol-
lowing data using a pre-standardized data extraction
form: characteristics of the study design; participants; in-
terventions; outcomes event rates and follow-up.
Reviewers independently assessed risk of bias by using a
modified version of the Cochrane Collaboration’s tool for
assessing risk for bias tool [13] (http:/distillercer.com/re-
sources/) [14] that includes nine domains: adequacy of se-
quence generation, allocation sequence concealment,
blinding of participants and caregivers, blinding of data
collectors, blinding for outcome assessors, blinding of data
analysts, incomplete outcome data, selective outcome
reporting, and the presence of other potential sources of
bias not accounted for in the previously cited domains
[14]. For incomplete outcome data we stipulated as low
risk of bias loss to follow-up of less than 10 % and a differ-
ence of less than 5 % in missing data in intervention and
control groups.
Certainty of evidence
The reviewers used the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
methodology to rate certainty of the evidence for each
outcome as high, moderate, low, or very low [15]. De-
tailed GRADE guidance was used to assess overall risk
of bias [16], imprecision [17], inconsistency [18], indir-
ectness [19] and publication bias [20], and summarized
results in an evidence profile. We assessed publication
bias through visual inspection of funnel plots for 10 or
more studies.
For decisions regarding eligibility, risk of bias assess-
ment, and data abstraction, reviewers resolved disagree-
ment through discussion with third party adjudication if
necessary.
Data synthesis and statistical analysis
We chose six months as a follow-up time that repre-
sented duration important to patients, sufficient to in-
clude most events that would likely be influenced by
thrombectomy, and would include relatively few
events that would not be potentially influenced by
thrombectomy. For meta-analyses we used six months
data if available; and otherwise we chose the time
point closest to six months, but preferring 1-year over
30 days.
We calculated pooled risk ratios (RRs) and associated
95 % confidential intervals (CIs) using random-effects
models with statistical method of Mantel-Haenszel. Ab-
solute effects and 95 % CI were calculated by multiply-
ing pooled RRs and 95 % CI by baseline risk estimates
derived from the TOTAL study (the most recent and lar-
gest of the included RCTs) [6]. We addressed variability
in results across studies by using I2 statistic and the P
value obtained from the Cochran chi square test. Our
primary analyses were based on eligible patients who
had reported outcomes for each study (complete case
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analysis). For overall mortality we used all-cause mor-
tality when available. For studies that did not present
all-cause mortality we used cardiovascular mortality.
We assessed publication bias through visual inspec-
tion of funnel plots for outcomes addressed in 10 or
more studies. Review Manager (RevMan) provided the
software for all analyses (version 5.3; Nordic Cochrane
Centre, Cochrane) [21].
We also performed a meta-regression with a fixed-
effect model using restricted estimated maximum likeli-
hood with an observed log-odds ratio to predict whether
mortality and recurrent myocardial infarction rates
changed significantly by mean age. Meta-regression




Our search strategy focusing on publications since the
last review identified 103 unique citations (Fig. 1).
After title and abstract screening, we assessed the
full-text version of 38 relevant citations. In addition,
we identified 42 potentially eligible publications in-
cluded in previous systematic reviews, six [6, 22–26]
of which were also identified in our search strategy.
Thereafter, we assessed eligibility of 74 unique publi-
cations and excluded 49 studies (Fig. 1). As a result,
we included 25 publications documenting 20 random-
ized controlled trials [6, 25–48] involving 21,660 par-
ticipants. Two studies [28, 35] and one updated
follow-up [46] were not included in any of the previ-
ous reviews.
Study characteristics
Ten studies [26, 27, 29, 31–34, 39–41, 43–46] were
conducted largely in Europe (Table 1). Sample size
ranged from 56 [35] to 10,732 [6] patients of whom
a majority were males with mean ages typically in
the early 60s. Studies included adult STEMI patients
typically with symptoms lasting >30 min but
<12 hours, and cumulative ST-segment elevation of
Fig. 1 Flowchart of the review
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Table 1 Study characteristics
Author, year Location No.
patient
Mean age (SD) No. male (%) Inclusion criteria Exclusion criteria Follow-up time
(months)
Outcomes evaluated
ADMIT [28] Haifa, Israel 100 I = 57.5 (12.4) 86 (86.0) Admission <12 hours of onset of
symptoms of STEMI, regardless of
the initial TIMI flow
Inability to consent; known allergy to
either aspirin or clopidogrel; life
expectancy <6 months; cardiogenic
shock
6 months Quality of epicardial and
microcirculation perfusion; LV
function; ischemic mitral
regurgitation; MACE (death, recurrent
MI, TVR)
C = 57.2 (12.1)
Bulum 2012 [29] Zagreb,
Croatia
60 I = 54.3 (9.7) 47 (78.3) Symptoms suggesting acute
myocardial ischemia of >20 min,
time from symptom onset of
<12 hours, and ST-segment elevation
>0.1 mV in >2 contiguous ECG leads
Need for rescue PCI after failed
thrombolysis; cardiogenic shock;
triple-vessel disease; significant LMCA
stenosis; previous PCI of an IRA; pre-
vious CABG; life expectancy
<6 months
6 months Referent vessel diameter; minimal
lumen diameter; lesion length;
percentage of diameter stenosis; MACE
(death, recurrent MI, stroke, TLR)
C = 58.5 (8.6)
Chao 2008 [30] Taipei City,
Taiwan
74 I = 60 (13) 63 (85.1) STEMI (typical chest pain >30 min
with new ST-segment elevation
≥0.1 mV in >2 contiguous leads on
a 12-lead ECG), <12 hours after
onset, and eligible for primary PCI
Killip IV hemodynamic status;
ventricular tachyarrhythmias;
previous CABG or significant LMCA
lesion; culprit vessel diameter
<2 mm; existing TIMI 3 flow without
visible thrombus in IRA
6 months Angiographic differences in TIMI and
MBG (post PCI - baseline); MACE
(death, stroke, non-fatal recurrent MI,
TVR)
C = 62 (11)
De Luca 2006
[31]
Rome, Italy 76 I = 66.7 (14.1) 48 (63.2) Anterior STEMI, >18 years old, and
have an identifiable thrombus on
IRA at coronary angiography
Previous MI or CABG; triple-vessel
disease; severe valvar disease; TIMI 2
or 3 flow at the time of initial
angiography; unsuccessful PCI
defined as no antegrade flow or
>50 % residual stenosis in the IRA
6 months LV remodeling; MACE (death,
recurrent MI, hospitalization for HF)
C = 64.6 (12.5)
EXPIRA [32, 33] Rome, Italy 175 I = 66.7 (14.1) 105 (60.0) First STEMI, <9 hours from
symptoms onset, IRA ≥2.5 mm in
diameter, thrombus score ≥ 3, TIMI
flow ≤1, and >18 years old
Previous PCI on IRA; previous CABG;
cardiogenic shock; triple-vessel disease;
LMCA disease; severe valvular disease;
thrombolysis; contraindication to
glycoprotein IIb/IIIa inhibitors
9 months Final MBG ≥2; rate of 90-min ST-
segment resolution >70 %; MACE
(cardiac death, recurrent MI, TVR);
stent thrombosis
C = 64.6 (12.5)
EXPORT [34] 24 centres in
India and
Europe
249 I = 59.2 (12.8) 202 (81.1) >18 years old, STEMI <12 hours of
symptom onset, ST-segment elevation
≥2 mm in ≥2 contiguous leads, visual
reference vessel diameter >2.5 mm, and
with TIMI flow of 0 or 1 before placing
the wire in the IRA
Cardiogenic shock; cardiac arrest
prior to intervention; pre-
catheterization therapy with lytic
agents, or with glycoprotein IIb/IIIa
inhibitors, or with pacemakers; life
expectancy <1 year; current
participation in other investigations
1 month Reperfusion (rate of ST-segment
resolution >50 % at 60 minutes
postprocedure or MBG 3 immediately
postprocedure); magnitude of
ST-segment resolution; improvement in
TIMI flow; corrected TIMI frame count;
MACE (death, recurrent MI, emergent
CABG, TLR or TVR, stroke); rate of distal
embolization; rate of required bailout
techniques (rescue use of the aspiration
catheter, distal protection, or glycopro-
tein IIb/IIIa inhibitors)
C = 61.2 (12.9)
IMPACT [35] Cambridge, UK 56 I = 64.9 (11.2)
C = 67.2 (11.6)
31 (55.3) >18 and <90 years old, ability to
give informed consent, STEMI (ST-
segment elevation ≥2 mm in ≥2
contiguous chest leads or ≥1 mm in
≥2 contiguous limb leads) or new
LBBB, chest pain for <12 hours,
restoration of at least TIMI 1 flow
after the wire crossed the occlusion
Cardiogenic shock; previous MI in
the IRA territory; unfavourable
anatomy (LMCA occlusion or distal
vessel occlusion); severe asthma or
bradycardia precluding use of
adenosine; women of childbearing
age; life expectancy <3 months
6 months Index of microcirculatory resistence;














Table 1 Study characteristics (Continued)
INFUSE-AMI
[36, 37]
37 sites in 6
countries
452 I = 61 (NR) 334 (73.9) ≥18 years old, STEMI with ≥1 mm of
ST-segment elevation in ≥2 contiguous
leads in V1 through V4 or new LBBB
with anticipated symptom onset to
device time of ≤5 hours
Prior MI, CABG or LAD stenting;
contraindications to study
medications, contrast or CMRI;
creatinine clearance <30 mL/min per
1.73 m2 or dialysis; platelet count
<100,000 or >700,000 cells/mm3;
hemoglobin <10 g/dL; recent major
bleeding; bleeding diathesis; current
warfarin use; intracranial disease,
stroke or TIA within 6 months or any
neurological defect; cardiogenic
shock; prior fibrinolysis or
glycoprotein IIb/IIIa inhibitors for the
present admission; any comorbid
likely to interfere with protocol
compliance or associated with
<1 year survival
12 months Infarct size measured as a
percentage of LV mass at 30 days.
MACE (death, recurrent MI, new-
onset severe HF, re-hospitalization for
HF, stroke, clinically driven TVR)




100 I = 60.4 (11.9) 86 (86.0) ≥18 years old, continuous
chest pain ≥30 min, ST-segment
elevation >0.1 mV in ≥2 contiguous
leads on a 12-lead ECG
Cardiogenic shock (systolic BP >
80 mmHg or need for inotropic
agent); history of bleeding tendency,
major operation within 6 weeks;
hepatic or renal insufficiency;
contraindication to tirofiban use
6 months Occurrence of MBG 3; complete ST-
segment resolution; procedure time;
occurrence of no-reflow; CK-MB peak
and time to peak; TIMI flow and
corrected TIMI frame count; MACE
(death, recurrent MI, TLR, stroke)
C = 56.5 (11.9)
Kaltoft 2006 [39] Aarhus,
Denmark
215 I = 65 (11) 168 (78.1) STEMI, symptoms lasting >30 min
but <12 hours, and cumulative
ST-segment elevation of ≥2 mV in
≥2 contiguous leads
LBBB; MI within the previous 30 days;
fibrinolytic treatment; previous CABG;
LCA stenosis; need for mechanical
ventilation; severe HF treated with
intra-aortic balloon pump
1 month Myocardial salvage estimated by
99mTc-sestamibi SPECT; final infarct
size; markers of effective reperfusion
(TIMI flow, corrected TIMI frame
count, ST-segment resolution
immediately, 90 min and 6 hours
after PCI); release of TnT; distal
embolization visible at the end of
PCI; total procedure time; MACE
(death, recurrent MI, disabling stroke);
LVEF after 30 days; technical success
of the thrombectomy
C = 63 (13)
Liistro 2009 [40] Arezzo, Italy 111 I = 64 (11) 86 (77.5) STEMI with symptoms lasting
>30 minutes and <12 hours,
ST-segment elevation >0.1 mV in ≥2
leads on the ECG
Contraindication to the use of
platelet glycoprotein IIb/IIIa
inhibitors; rescue PCI after
thrombolysis; previous MI; absence of
optimal echocardiographic apical
view; life expectancy <6 months; lack
of informed consent
6 months Rate of ST-segment resolution ≥70 %;
TIMI 3 grade flow; corrected TIMI frame
count; myocardial contrast echocardiog-
raphy score index; absence of persistent
ST-segment deviation; time course of
wall-motion score index; LVEF; LV
volume; death; recurrent MI; LV failure;
new revascularization
C = 65 (11)
REMEDIA [41] Rome, Italy 99 I = 61 (13) 83 (83.3) <12 hours of onset of STEMI referred
for primary or rescue PCI
No angiographic exclusion criteria
were adopted
1 month MBG ≥2; rate of ST-segment resolution
≥70 %; peak CK-MB; direct stenting rate;
distal embolization rate (abrupt “cutoff”
occlusion of a distal branch); composite
of distal embolization, slow-flow (TIMI
flow grade 2), no-reflow (TIMI flow
grade 0 to 1); death; recurrent MI; stroke;
TLR; any major adverse event














Table 1 Study characteristics (Continued)
Shehata 2014
[25]
Cairo, Egypt 100 I = 60.32 (9.2) 64 (64) Diabetic patients suffering from
acute STEMI, symptoms lasting
>30 minutes and <12 hours before
admission, and ST-segment elevation
of >0.1 mV in ≥2 leads
Need for rescue PCI after
thrombolysis; prior history of
unstable angina or MI; prior PCI
CABG; congenital heart disease or
any myocardial disease apart from
ischemia; limited life expectancy due
to coexistent disease
8 months In-stent restenosis (angiographic
luminal diameter stenosis by >50 %
in quantitative coronary
angiography); MACE (death due to
cardiac cause, nonfatal MI, TLR)
C = 59.4 (7.4)
Sim 2013 [42] Gwangju,
Republic of
Korea
86 I = 63 (NR) 59 (71.1) STEMI with onset of symptoms
<12 hours, coronary artery lesions
with visible thrombus, ability to
undergo a complete CCT
examination (Killip I and II) with the
ability to perform a15-second
breath-hold
Previous MI or CABG; cardiogenic
shock; LMCA disease; severe valvular
heart disease; unsuccessful PCI
(post-PCI TIMI flow <2 or ≥50 %
residual stenosis in IRA); rescue or
facilitated PCI; contraindication to
glycoprotein IIb/IIIa inhibitors
12 months Infarct size at 2 months; markers of
myocardial reperfusion (TIMI flow,
MBG, ST-segment resolution rate at
90 min); LV function and volumes at
2 months; MACE (cardiac death, MI,
TVR)
C = 60(NR)
TAPAS [43, 44] Groningen, The
Netherlands
1071 I = 63 (13) 755 (70.5) STEMI, symptoms >30 minutes and
<12 hours, and ST-segment elevation
of ≥0.1 mV in ≥2 leads
Rescue PCI after thrombolysis; life
expectancy <6 months; lack of
informed consent
1 month Rate of post-procedural MBG of 0;
rate of TIMI flow grade of 3;
complete resolution of ST-segment
elevation; absence of persistent
ST-segment deviation; TVR; recurrent
MI; death
C = 63 (13)
TASTE [26, 27] 29 centers in
Sweden, 1
center in
Iceland and 1 in
Denmark
7244 I = 66.5 (11.5) 5424 (74.9) STEMI, chest pain for >30 minutes and
<24 hours, ST-segment elevation in ≥2
contiguous leads (≥0.2 mV in lead V2
or V3 or ≥0.1 mV in other leads) or a
presumably new LBBB, and a
corresponding culprit-artery lesion
on angiography
Need for emergency CABG; inability
to provide oral informed consent;
<18 years old; previously randomized
in the study
12 months MACE (all-cause mortality;
rehospitalization for MI; stent
thrombosis); TVR; TLR; complications
of PCI, stroke or neurologic
complications, HF and length of stay
during index hospitalization
C = 65.9 (11.7)
TOTAL [6] 87 hospitals in
20 countries
10732 I = 61.0 (11.8) 7797 (72.6) Symptoms of MI lasting for ≥30 min,
definite ECG changes indicating
STEMI, referred for PCI for presenting
symptoms, randomized within
12 hours of symptoms onset and
before diagnostic angiography,
Informed consent
≤18 years old; prior CABG; life
expectancy <6 months due to
noncardiac condition; treatment with
fibrinolytic therapy for qualifying
index STEMI event
6 months MACE (cardiovascular death,
recurrent MI, cardiogenic shock, HF
NYHA class IV); strokeC = 65.0 (11.9)
TROFI [45, 46] 5 european
centres
141 I = 61.1 (11.8) 102 (72.3) ≥18 years old, STEMI documented
with ≥2 mm ST-segment elevation
in ≥2 contiguous leads prior to PCI,
presenting in the cath lab <12 hours
after the onset of symptoms lasting
≥20 min and having an angiographically
visible stenosis (>30 %) or TIMI≤ II in a
single de novo, native, previously
unstented vessel
Pregnancy; known intolerance to
aspirin, clopidogrel, heparin, stainless
steel, limus drugs, contrast material;
diameter stenosis <30 % in the target
lesion; multi-vessel CAD; unprotected
LMCA stenosis >30 %; distal vessel
occlusion; severe tortuous, calcified or
angulated anatomy that would result in
sub-optimal imaging or excessive risk
of complication from insertion of
catheter; fibrinolysis prior to PCI; platelet
<100,000 cells/μl; coagulopathy or active
bleeding or chronic anticoagulation
therapy; cardiogenic shock; significant
comorbidities precluding follow-up as
judged by investigators; major planned
surgery requiring discontinuation of
antiplatelets; proximal RCA stenosis
(>30 %) if the IRA is mid or distal-RCA
12 months Minimum flow area immediately
after PCI assessed by OFDI; MACE
(cardiac death, recurrent MI in the
territory of IRA, clinically driven TVR)














Table 1 Study characteristics (Continued)
VAMPIRE [47] 23 hospitals in
Japan
355 I = 63.2 (10.6) 281 (79.1) ≥21 years old, STEMI symptom
>30 min but <24 hours, ST-segment
elevation ≥2 mm in ≥2 contiguous
leads or with a presumably new
LBBB
Primary thrombolysis prior to
randomization; cardiogenic shock;
history of cardiac arrest; history of
CABG; chronic renal failure (Cr
>2.0 mg/dl) or hemodialysis; LMCA
disease; target vessel <2.5 mm or
>5 mm in diameter
8 months Incidence of slow flow or no reflow
during primary PCI (TIMI flow grade
<3 not attributable to dissection,
occlusive thrombus, or epicardial
spasm); coronary flow and
myocardial perfusion immediately
after PCI (assessed by TIMI flow
grade, corrected TIMI frame count
and MBG); magnitude of ST-segment
resolution, peak CK and CK-MB;
angiographic in-stent late lumen loss;
LV function; brain natriuretic peptide;
MACE (death, recurrence MI, TLR)
C = 63.5 (9.9)
Yin 2011 [48] Dalian, China 164 I = 63.1 (12.9) 120 (73.2) STEMI patients who had PCI Not reported 12 months Thrombus score; periprocedural
no-reflow; TIMI frame count; lumen
diameter; stent length; 1-week
post-procedural ejection fraction;
post-procedural angina; recurrent MI;
death
C = 62.9 (9.5)
SD standard deviation, no. number, I intervention group, C control group, STEMI ST-segment elevation myocardial infarction, TIMI thrombolysis in myocardial infarction, LV left ventricular, MACE major adverse cardiac
events, MI myocardial infarction, TVR target vessel revascularization, ECG electrocardiogram, PCI percutaneous coronary intervention, LMCA left main coronary artery, IRA infarct-related artery, CABG coronary artery
bypass grafting, TLR target lesion revascularization, MBG myocardial blush grade, HF heart failure, LBBB left bundle branch block, NR not reported, LAD left anterior descending, CMRI cardiac magnetic resonance
imaging, TIA transient ischemic attack, SPECT single-photon emission computed tomography, TnT troponin T, LVEF left ventricular ejection fraction, CK-MB creatine kinase myocardial band, CCT cardiac computed














>0.1 mV in ≥2 leads. Some studies excluded life ex-
pectancy < 6 months [6, 28, 29]; cardiogenic shock
[28, 29, 32, 33, 35–38, 45–47]; previous CABG or
MI or significant left main coronary lesion [6, 25,
29–33, 35–37, 39, 40, 42, 45–47]; pre-catheterization
therapy with lytic agents [34]; severe asthma or
bradycardia precluding use of adenosine [35]; dialy-
sis; platelet count <100,000 or >700,000 cells/mm3;
hemoglobin <10 g/dL [36, 37]; severe HF treated
with intra-aortic balloon pump [39]; contraindication
or prior use of platelet glycoprotein IIb/IIIa inhibi-
tors [32–34, 40, 42]; rescue or facilitated PCI [42–
44]; need for emergency CABG [26, 27]; pregnancy
[45, 46]; and major planned surgery requiring dis-
continuation of antiplatelets agents [45, 46]. Follow-
up time ranged from 30 to 360 days.
Table 2 Study protocol used as preprocedure reported by the included studies
Author, year Different regimens of anti-aggregation/anticoagulation used
ADMIT [28] Oral aspirin 300 mg as a loading dose (or only 100 mg if the patient was on aspirin therapy) continued by 100 mg/day
indefinitely, 600 mg clopidogrel loading dose continued by 75 mg/day for one year and IV 60 mg/ kg unfractionated heparin
as loading dose to keep activating clotting time during procedure > 250 second.
Bulum 2012 [29] 300 mg of aspirin and 600 mg of clopidogrel and a weight-adjusted dose of unfractionated heparin; the usage of glycoprotein
IIb/IIIa inhibitor (eptifibatide) was left to the discretion of the operator.
Chao 2008 [30] Aspirin 300 mg and clopidogrel 300 mg were given as loading dose, with intravenous heparin 70– 100 U/kg to achieve
activated clotting time (ACT) > 200 s prior to intervention.
De Luca 2006 [31] Aspirin 300 mg orally and heparin 8000 IU intravenously before the procedure and abciximab as a 0.25 mg/kg bolus and
0.125 mg/kg/min intravenous infusion immediately before the revascularisation and continued for 12 hours.
EXPIRA [32, 33] Aspirin 300 mg, intravenous heparin, abciximab at a standard dose, and clopidogrel 300 mg before the revascularization.
EXPORT [34] The choice of medication during the procedure such as aspirin, heparin, clopidogrel, and glycoprotein IIb/IIIa inhibitors was also
at the investigator’s discretion, and were administrated according to standard hospital procedure.
IMPACT [35] Aspirin 300 mg and clopidogrel 600 mg preloading in the ambulance and anticoagulated with a heparin bolus (70–100 U/kg)
after arterial sheath insertion to achieve an activated clotting time (ACT) >250 s. Adjunctive pharmacotherapy, including
abciximab and bivalirudin, was given at the operator’s discretion.
INFUSE-AMI [36, 37] Patients undergoing primary PCI received bivalirudin anticoagulation.
ITTI [38] Aspirin (300 mg loading followed by 100 mg daily) and clopidogrel (300 mg loading followed by 75 mg daily) and
unfractionated heparin 100 IU/kg.
Kaltoft 2006 [39] Aspirin 300 mg orally or intravenously, clopidogrel 300 mg orally, and unfractionated heparin 10 000 IE intravenously. During
the intervention, all patients were treated with abciximab.
Liistro 2009 [40] Aspirin (a loading dose of 500 mg), heparin (70 IU/kg), and clopidogrel (a loading dose of 600 mg). All patients also received
the glycoprotein IIb/IIIa inhibitor abciximab with an intravenous procedural bolus of 0.25 mg/kg followed by a continuous
intravenous infusion of 0.125 μg/kg/min for 12 hours and postprocedural infusion without heparin.
REMEDIA [41] Heparin (initial weight-adjusted IV bolus then further boluses administered with the aim of obtaining an activated clotting time
of 250 to 300 s in patients treated with abciximab and > 300 s in the remaining subjects) and with double antiplatelet therapy
with aspirin and clopidogrel (loading dose of 300 mg followed by 75 mg/day) for at least four weeks. Unless contraindicated,
abciximab (0.25 mg/kg bolus plus infusion of 0.125 μg/kg/min for 12 h) was intravenously administered in all patients undergoing
primary PCI, whereas in those with failed thrombolysis, abciximab use was left to the operator’s discretion.
Shehata 2014 [25] Aspirin (a loading dose of 500 mg), heparin (70 IU/kg), and clopidogrel (a loading dose of 600 mg). All patients also received
the glycoprotein IIb/IIIa inhibitor abciximab with an intravenous procedural bolus of 0.25 mg/kg followed by a continuous
intravenous infusion of 0.125 g/kg/min for 12 hours and postprocedural infusion without heparin.
Sim 2013 [42] Aspirin 300 mg, clopidogrel 600 mg, intravenous unfractionated heparin and nitroglycerin. Oral atenolol 50–100 mg was given
to optimize heart rate≤ 65 beats per minute prior to CT scan, unless contraindicated.
TAPAS [43, 44] Aspirin (a loading dose of 500 mg), heparin (5000 IU), and clopidogrel (a loading dose of 600 mg). Patients also received the
glycoprotein IIb/IIIa inhibitor abciximab, with the dose based on body weight, unless contra-indicated, and additional heparin,
with the dose based on the activated clotting time.
TASTE [26, 27] Patients received the following procedure-related medication: bivalirudin, clopidogrel or ticlopidine, acetylsalicylic acid, ticagrelor,
prasugrel, heparin, low-molecular-weight heparin, and glycoprotein IIb/IIIa blocker. The use of platelet inhibitors or anticoagulants
was left to the discretion of the treating physician.
TOTAL [6] Unfractionated heparin; bivalirudin; enoxaparin and; glycoprotein IIb/IIa inhibitor.
TROFI [45, 46] Heparin in ambulance.
VAMPIRE [47] Aspirin and intravenous heparin boluses were administered during the procedure to maintain an activated clotting time≥ 300 s.
Yin 2011 [48] Aspirin 300 mg and clopidogrel 300 mg prior to angiography.
IV: intravenous
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Twelve studies [25, 28–30, 34, 35, 38–44] used as-
pirin and clopidogrel as a preprocedure antithrom-
botic therapy; some of them [6, 25–30, 32–35, 38, 39,
41–47] also used intravenous heparin; seven of them
had all patients were treated with abciximab [25, 31,
35, 39, 40, 41, 43, 44] and; one of them [42] also
used nitroglycerin (Table 2).
The choice of medication during the procedure
such as aspirin, heparin, clopidogrel, and glycoprotein
IIb/IIIa inhibitors was at the investigator’s discretion
in one of the included studies [34]. The patients in
one further trial [26, 27] received the following
procedure-related medication: bivalirudin, clopidogrel
or ticlopidine, acetylsalicylic acid, ticagrelor, prasugrel,
heparin, low-molecular-weight heparin, and glycopro-
tein IIb/IIIa blocker, while in other one [6] patients
received unfractionated heparin; bivalirudin; enoxa-
parin and; glycoprotein IIb/IIa inhibitor (Table 2).
Patients in TROFI trial [45, 46] received only heparin
in ambulance and, in VAMPIRE trial [47] aspirin and
intravenous heparin boluses were administered during
the procedure to maintain an activated clotting time ≥
300 s.
Risk of bias assessment
A possibly important limitation with respect to risk of
bias was lack of blinding for caregivers. A number of
studies, including the larger ones, blinded the adjudica-
tors of outcome. Follow-up was largely satisfactory: 14
trials lost less than 10 % of patients to follow-up (Table 3
and Fig. 2).































could put it at
a risk of bias?
ADMIT (28) Yes Yes No Probably no Probably yes Probably no Yes Yes Yes
Bulum 2012 (29) Probably no Probably no No No No No Yes Yes Yes
Chao 2008 (30) Probably yes Probably no No No No No Yes Probably
yes
Yes
De Luca 2006 (31) Probably no Probably no No Probably no Probably no Probably no No Yes Yes





EXPORT (34) Yes Yes No No Yes No Yes Probably
no
Probably yes
IMPACT (35) Probably no Probably no No Probably no Probably no Probably no No No Yes
INFUSE-AMI (36, 37) Yes Probably no No Probably no Yes Probably no Yes Yes No
ITTI (38) Yes Probably no No Probably no Probably yes Probably no Yes Yes Yes
Kaltoft 2006 (39) Yes Yes No Probably no Probably no Probably no Yes Yes Yes
Liistro 2009 (40) Yes Probably no No No Probably yes No Probably
yes
Yes Yes
REMEDIA (41) Yes Probably yes No No No No Probably
yes
Yes Probably yes
Shehata 2014 (25) Yes Yes No Probably no Yes Probably no Yes Yes Yes
Sim 2013 (42) Probably no Probably no No No No No Yes Probably
no
Yes
TAPAS (43, 44) Yes Probably yes No No Yes No Yes Yes Yes
TASTE (26, 27) Yes Yes No No No Probably no Yes Yes Yes
TOTAL (6) Yes Yes No Probably no Yes Probably yes Yes Yes Probably no
TROFI (45, 46) Yes Yes No No Yes Probably no Yes Yes Yes
VAMPIRE (47) Probably yes Probably
no
No No Yes No No Yes Probably yes
Yin 2011 (48) No No No No No No No No Probably no
aDefined as less than 10 % loss to outcome data or difference between groups less than 5 % and those excluded are not likely to have made a material difference
in the effect observed
All answers as: yes (low risk of bias), probably yes, probably no, no (high risk of bias)
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Outcomes
Appendix Table 2 presents the mortality data by indi-
vidual study and Appendix Table 3 presents individual
study outcome data for recurrent MI, stroke, and
bleeding.
Overall mortality
In 20 trials [6, 25–48] that addressed overall mortal-
ity, 457 of 10,433 (4.4 %) patients died in the control
arm compared to 403 of 10,433 (3.9 %) in the aspir-
ation PCI arm (relative risk (RR) 0.89, 95 % CI 0.78
to 1.01; I2 = 0 %; risk difference (RD) 4/1,000 over
6 months; moderate certainty) (Fig. 3). Certainty in
evidence was rated down to moderate because of im-
precision and unblinding of caregivers in all included
studies (Table 4).
Recurrent myocardial infarction
In 17 trials [6, 25–29, 31–34, 36–41, 43–48], 246 of
10,331 (2.4 %) patients suffered a recurrent MI in the
control arm compared to 229 of 10,331 (2.2 %) in the
aspiration PCI arm (RR 0.94, 95 % CI 0.79 to 1.12;
I2 = 0 %; RD 1/1,000 over 6 months; moderate cer-
tainty) (Fig. 4). Certainty in evidence was rated down
to moderate because of imprecision, lack of blinding
of caregivers in all included studies and inadequate
or unreported blinding of outcome adjudicators in
some studies [26, 27, 29, 31, 39, 41, 48] (Table 4).
Stroke
In 8 trials [6, 26, 27, 29, 36–39, 41, 45, 46], 77 of 9,185
(0.8 %) patients that underwent aspiration PCI use had
a stroke compared to 48 of 9,162 (0.5 %) in the PCI
alone (RR 1.56, 1.09 to 2.24; I2 = 0 %; RD 3/1,000 over
6 months; moderate certainty) (Fig. 5). Certainty in
evidence was rated down to moderate because of im-
precision, lack of blinding of caregivers in all included
studies and inadequate or unreported blinding of out-
come adjudicators in some studies [26, 27, 29, 39, 41]
(Table 4). We intended to evaluate non-fatal stroke,
but data was not available in sufficient number of stud-
ies to provide a useful comparison.
Major bleeding
In 4 trials [6, 36–38, 43, 44], 99 of 5823 (1.7 %) pa-
tients presented major bleeding in the control arm
compared to 101 of 5,832 (1.7 %) in the aspiration
PCI arm (RR 1.02, 0.78 to 1.35; I2 = 0 %; RD 0/1,000
over 6 months; moderate certainty) (Fig. 6). Certainty
in evidence was rated down to moderate because of
imprecision and lack of blinding of caregivers in all
included studies (Table 4).
Fig. 2 Risk of bias assessment
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More than 10 studies addressed overall mortality and
recurrent MI; for both, funnel plots did not suggest pub-
lication bias (Appendix: Figures 1 and 2).
Meta-Regression analysis
Data from studies assessed in a meta-regression
showed that the relationship between mortality rates
decreased with increasing mean age; however was not
significant (slope: −0.011; 95 % confidence interval:
−.0980 to .0765; P = 0.784; Fig. 7). Similarly, the rela-
tionship between recurrent myocardial infarction rates
decreased with increasing mean age; however was not
significant (slope: −0.011; 95 % confidence interval:
−.1175 to .0944; P = 0.811; Fig. 8).
Discussion
Main findings
Based on pooled data from 20 randomized trials with
more than 20,000 patients, we found moderate quality
evidence for a non-statistically significant reduction in
overall mortality (4 fewer deaths/1000 treated over
6 months) (Table 4) and a small potential increase in
stroke (3 additional strokes/1000 treated over 6 months)
(Table 4) in patients treated with thrombectomy. Moder-
ate quality evidence suggests no impact of thrombec-
tomy on either recurrent MI or major bleeding
(Table 4).
A number of factors decreased our certainty in the
estimates for overall mortality. In particular, the con-
fidence interval included both no reduction in deaths
and a mortality reduction that although small (8
fewer deaths in 1,000 over six months), many would
consider important. Similarly with stroke: the confi-
dence interval includes no increase in stroke and an
increase of 6 more strokes in 1,000 patients over
6 months with thrombectomy, which many would
consider an important risk. Other issues decreasing
confidence in our estimates included potential risk
of bias imposed by lack of blinding of patients and
health care providers in all studies, and lack of
blinding of outcome adjudicators in some studies.
The meta-regression analyses showed that both
mortality and recurrent myocardial infarction rates
decreased with increasing mean age. However, there
was a non-significant difference between these two
variables and the mean age of participants in both
studied groups. A study [49] evaluated through a
meta-regression whether there is an association be-
tween age, gender, diabetes mellitus, previous myo-
cardial infarction and ejection fraction, and the
choice of revascularization, focusing on death, myo-
cardial infarction, repeat revascularization and
stroke. The authors found that the reduction in
stroke was significantly higher in females, and that
women and patients with diabetes mellitus were at
increased risk of subsequent revascularization after
PCI [49].
Strengths and limitations
Strengths of our review include a comprehensive search;
assessment of eligibility, risk of bias, and data abstrac-
tion independently and in duplicate; use of the GRADE
Fig. 3 Meta-analysis comparing aspiration PCI versus conventional PCI on overall mortality
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Table 4 GRADE evidence profile: Aspiration thrombectomy (AT) prior to PCI in patients with STEMI
Quality assessment Summary of findings Certainty in estimates
Study event rates Relative risk
(95 % CI)
Anticipated absolute effects over6
months
OR Quality of evidence
No of participants(studies)
Range follow-up time
Risk of bias Inconsistency Indirectness Imprecision Publication bias Without AT With AT Without AT With AT
Overall mortality (Includes cardiovascular (CV) mortality for studies only reporting CV mortality)








Undetected 457/ 10433 403/ 10433 0.89 (0.78-1.01) 35 per 10004 4 fewer per 1000

















0.94 (0.79-1.12) 18 per 10004 1 fewer per 1000
















1.56 (1.09-2.24) 5 per 10004 3 more per 1000
















1.02 (0.78-1.35) 15 per 10004 0 more per 1000
(3 fewer to 5 more)
⊕⊕⊕⊕O MODERATE,
due to imprecision
1No studies were blinded to patient or caregiver. Some studies (minority of subjects enrolled) did not indicate blinded adjudication. While not specifically rating down for risk of bias, these additional concerns plus borderline
clinically important imprecision led to downgrading of certainty in estimates for all outcomes
2Some studies only report cardiovascular and not all cause mortality. However cardiovascular mortality constituted significant proportion of overall mortality in studies reporting both types of mortality. Therefore we opted against
rating down for indirectness
395% CI for absolute effects include clinically important benefit and no benefit
4Baseline risk estimates for mortality, recurrent MI, stroke, and major bleeds come from control arm of TOTAL study (largest and most recent randomized trial)
595% CI for absolute effects include benefit and harm














approach in rating the quality of evidence for each
outcome; and focus on absolute as well as relative ef-
fects of the intervention on patient-important out-
comes. In this case, the small and more or less
equivalent number of possible deaths prevented and
strokes caused by thrombectomy, and the uncertainty
consequent on the imprecision and risk of bias issues,
are crucial in considering patient management
(Table 4).
Potential limitations are related to the available data.
Trials often suffered from incomplete outcome report-
ing, and lack of blinding consequent on the nature of
the intervention, but for some studies also avoidable lack
of blinding (outcome adjudication).
Relation to prior work
Recently published results from another meta-
analysis [50] as well as data from a limited meta-
analysis conducted as part of an evaluation of the
outcome of stroke in the TOTAL study [12] are in
general consistent with our findings. Results from
all three analyses are in general consistent with our
findings. Our systematic review and meta-analysis
nevertheless adds important information as a result
of our comprehensive assessment of risk of bias
issues, our use of a complete case analysis that
avoids assumptions regarding patients lost to fol-
low-up, our use of the GRADE approach to rate
quality of evidence, and our focus on absolute effects
of thrombectomy required for optimal decision-
making.
Furthermore, another review compared the effects
of thrombectomy as an adjunct to PCI in the man-
agement of acute myocardial infarction in 20,853
patients [51]. The authors concluded that mortality;
reinfarction and; stent thrombosis rates did not dif-
fer significantly between patients treated with or
without AT; but stroke rates were increased with
AT [51].
Fig. 4 Meta-analysis comparing aspiration PCI versus conventional PCI on recurrent myocardial infarction
Fig. 5 Meta-analysis comparing aspiration PCI versus conventional PCI on stroke.
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Fig. 7 Meta-regression of mortality rates by mean age. Each circle represents a study highlighted by its weight in the analysis. The relationship
between mortality and mean age in both groups was not significant (slope: -0.011; 95 % confidence interval: -.0980 to .0765; P = 0.784)
Fig. 6 Meta-analysis comparing aspiration PCI versus conventional PCI on major bleeding
Fig. 8 Meta-regression of recurrent myocardial infarction rates by mean age. Each circle represents a study highlighted by its weight in the
analysis. The relationship between recurrent myocardial infarction and mean age in both groups was not significant (slope: -0.011; 95 %
confidence interval: -.1175 to .0944; P = 0.811)
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Implications
The possible magnitude of benefit with respect to mor-
tality and magnitude of harm with respect to stroke are
small – some might say very small – and similar both
with respect to magnitude and likelihood that the effects
are real. With respect to mortality, the most likely mech-
anism of benefit would be a reduction in recurrent MI;
the data, however, provide no support for an impact of
thrombectomy on MI.
Similarly the mechanism of an increase in stroke is
not immediately apparent. In a recent analysis of data
from the TOTAL study, thrombectomy was associated
with a small increase in procedure time as well as in-
creased use of larger catheters (99.2 % vs. 97.5 % > 5
French) [12]. One could postulate this could lead to an
increase in embolization of aortic atherosclerotic plaque
leading to increased early ischemic events. More fre-
quent development of subsequent atrial fibrillation
would constitute another possible mechanism; no study
reported this outcome.
Initial enthusiasm for thrombectomy was motivated
by evidence of improvement in markers of myocar-
dial tissue reperfusion. Our findings emphasize the
need for caution with respect to surrogates, and the
desirability of focus on outcomes important to pa-
tients. While it is not routinely justified there may
be individual cases in which an operator may feel
the potential benefit of the procedure outweighs po-
tential risks.
The absolute effects of thrombectomy prior to pri-
mary PCI are very small and still associated with un-
certainty. Given the best estimates of effect and
associated quality of evidence, fully informed risk ad-
verse patients - and particularly those who are highly
stroke risk averse - would likely decline thrombec-
tomy. Patients who place high value on an uncertain
mortality reduction and have limited concern regard-
ing a possible stroke increase would be more likely to
choose to undergo the procedure. Given current con-
cerns regarding overtreatment and efficient use of
health care resources, a policy decision to not use
thrombectomy in a particular catheterization labora-
tory is defensible.
Conclusions
Moderate certainty evidence suggests aspiration
thrombectomy is associated with a possible small de-
crease in mortality (4 less deaths/1000 over
6 months) and a small increase in stroke (3 more
strokes/1000 over 6 months). Because absolute ef-
fects are very small and closely balanced, thrombec-
tomy prior to primary PCI should not be used as a
routine strategy.
Appendix
Table 5 Search strategy
Ovid MEDLINE(R) 1946 to present with daily update
Ovid MEDLINE(R) in-process & other non-indexed citations June 24, 2015
1. myocardial infarction.ti,ab 194029
2 *Infarction/ 4551
3 Myocardial Infarction/ 145002
4 or/1-3 201604
5 thrombus aspiration.ti,ab. 400
6 thromboaspiration.ti,ab. 125
7 (aspiration adj5 mechanical).ti,ab. 214
8 Thrombectomy.ti,ab. 4995




13 randomized controlled trial.pt. 398533
14 controlled clinical trial.pt. 89780
15 randomized.ab. 324620
16 placebo.ab. 163833






23 exp animals/ not humans.sh. 4063058
24 22 not 23 346
Embase 1974 to 2015 June 24
1. Myocardial Infarction.ti,ab. 138908
2 heart infarction/ or acute heart infarction/ or infarction/
or ST segment elevation myocardial infarction/
298819
3 myocardial disease/ 4499
4 or/1-3 335897
5 thrombus aspiration.ti,ab. 899
6 thromboaspiration.ti,ab. 227
7 (aspiration adj5 mechanical).ti,ab. 328
8 Thrombectomy.ti,ab. 7683






15 (crossover$ or cross-over$).tw. 76738
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ADMIT [28] 41/43 6 4/41; 2/43
47/47 1 3/47; 1/47
Bulum 2012
[29]
30/30 6 0/30; 0/30
Chao 2008
[30]
37/37 6 NA 1/37; 0/37
De Luca 2006
[31]
35/38 6 0/35; 2/38
EXPIRA[32, 33] 88/87 24 0/88; 6/87 0/88; 6/87
88/87 9 0/88; 4/87 0/88; 4/87
EXPORT [34] 120/129 1 3/120; 5/129 3/120; 5/129
IMPACT[35] 20/21 6 1/20; 1/ 21 1/20; 1/ 21
INFUSE AMI
[36, 37]
222/207 12 NA 11/222; 15/
207
218/214 1 0/218; 1/214
ITTI [38] 52/48 6 1/52; 0/48
Kaltoft 2006
[39]
108/107 1 NA 0/108 ; 1/107
Liistro 2009
[40]
55/56 6 1/55; 0/56 1/55; 0/56
REMEDIA[41] 48/48 1 NA 3/48; 3/48
Shehata 2014
[25]
48/46 8 0/48; 1/46 0/48; 1/46
Sim 2013 [42] 43/43 12 NA 1/43; 0/43
TAPAS [43, 44] 530/530 12 19/530; 36/530 25/530; 41/
530
529/531 1 NA 11/529; 21/
531








TROFI [45, 46] 59/61 12 0/59; 1/61 0/59; 1/61
VAMPIRE [47] 170/158 8 2/170; 1/158
Yin 2011 [48] 73/91 12 NA 2/73; 4/91
*Preference for 6-month mortality, then any defined period closest to
6 months, however abstract in-hospital mortality if that is the only one
available was excluded from review
Table 5 Search strategy (Continued)
16 placebo$.tw. 221322
17 (doubl$ adj blind$).tw. 158296




22 Crossover Procedure.sh. 43314
23 Double-blind Procedure.sh. 123817
24 Randomized Controlled Trial.sh. 377450
25 Single-blind Procedure.sh. 20454
26 or/13-25 1582267
27 animals/ not humans/ 1258280
28 and/4,12,26 454
29 28 not 27 454
CENTRAL Issue 5 of 12, May 2015
#1 myocardial infarction:ti,ab,kw (Word variations have been
searched)
17426
#2 MeSH descriptor: [Infarction] explode all trees 18
#3 MeSH descriptor: [Myocardial Infarction] explode all trees 8885
#4 #1 or #2 or #3 17525
#5 thrombus aspiration:ti,ab,kw (Word variations have been
searched)
151
#6 thromboaspiration:ti,ab,kw (Word variations have been
searched)
10
#7 aspiration mechanical:ti,ab,kw (Word variations have
been searched)
251
#8 thrombectomy:ti,ab,kw (Word variations have been
searched)
336
#9 aspiration catheter*:ti,ab,kw (Word variations have been
searched)
293
#10 thrombosuction:ti,ab,kw (Word variations have been
searched)
4
#11 MeSH descriptor: [Thrombectomy] explode all trees 144
#12 #5 or #6 or #7 or #8 or #9 or #10 or #11 860
#13 #4 and #12 216
In Trials 195
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Table 7 Outcome data per study
Author, year No. included in analysis
(intervention/ control)
Follow-up time (Month) No. (%) of major bleeding
(intervention/ control)
No. (%) of non-fatal stroke
(intervention/ control)
No. (%) of recurrent
myocardial infarction
(intervention/ control)
ADMIT [28] 39/42 6 3(7.7)/3(7)
42/46 1 2(4.7)/0
49/51 0 1(2)/0
Bulum 2012 [29] 30/30 6 0/0 0/0
Chao 2008 [30] 37/37
De Luca 2006 [31] 35/38 6 1/0
EXPIRA [32, 33] 88/87 24 0/1(1.14)
EXPORT [34] 120/129 1 2(0.016)/1(0.77)
IMPACT [35] 20/21 6
INFUSE AMI [36, 37] 222/207 12 NA 2(0.9)/3(1.4) 1(0.45)/3(1.4)
218/214 1 2(0.9)/4(1.86) 0/1(0.46) 1(0.45)/2(0.93)
ITTI [38] 52/48 6 0/0 1(1.92)/0(0) 2(3.84)/5(10.41)
Kaltoft 2006 [39] 108/107 1 2(1.85)/0(0) 0/1(0.93)
Liistro 2009 [40] 55/56 3(5.4)/3(5.3)
REMEDIA [41] 48/48 1 1(2)/1(2) 2(4)/2(4)
Shehata 2014 [25] 48/46 8 4(8)/6(13)
Sim 2013 [42] 43/43 12
TAPAS [43, 44] 529/531 1 20(3.78)/18(3) 4(0.75)/10(1.88)
530/530 12 12(2.26)/23(4.3)
TASTE [26, 27] 3621/3623 12 19(0.52)/18(0.4)* 96(2.7)/99(2.7)
3621/3623 1 19(0.52)/31(0.85)
TOTAL [6] 5033/5030 6 79(1.5)/77(1.5) 52(1)/25(0.5) 99(2)/92(1.8)
5033/5030 1 33(0.65)/16(0.32)
TROFI [45, 46] 59/61 12 NA NA 1(1.7)/0
71/70 0 NA 0/1(1.4) 0/0
VAMPIRE [47] 170/158 8 0/1(0.6)
178/171 0 0/1(0.6)
Yin 2011 [48] 73/91 12 3(4)/6(6.6)
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Fig. 10
Fig. 9
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